Navigation Links
Genetic pathway can slow spread of ovarian cancer
Date:6/17/2014

University of Adelaide research into the origins of ovarian cancer has led to the discovery of a genetic pathway that could slow the spread of the cancer.

The discovery is in part due to research into the genetics of humans' most distant mammalian relative, the platypus.

In a paper published today in the journal PLOS ONE, researchers characterize a genetic pathway involving piRNA genes that is turned on in ovarian cancer.

"This pathway is important for the development of the ovaries in drosophila flies but little is known about its role in the mammalian ovary," says lead author Associate Professor Frank Grtzner, Genetics Lecturer and ARC Research Fellow with the University of Adelaide's Robinson Research Institute and the School of Molecular and Biomedical Science.

"We previously found that these genes are active in cells supporting oocyte (egg cell) development in platypus, mice and humans, just like in flies.

"We then decided to look into ovarian cancer and discovered that expression of these genes is turned up in this disease. We expected that these genes would promote the spreading of cancer cells but when we switched them on in ovarian cancer cell lines in the laboratory we observed the contrary, a suppression of spread.

"This result was very surprising, and we therefore looked back at the cancers and found that many RNAs, produced from one of the genes, are faulty," Associate Professor Grtzner says. "There have been previous studies in other cancers that have shown these genes actually increase growth and spread of cancer. We are only beginning to understand how this pathway might work in cancer and this work shows that it may act in completely different ways depending on the type of cancer. It also shows that these genes might be switched on in cancer but don't function properly."

The research team, involving University of Adelaide Professor Martin K. Oehler, Director of Gynecological Oncology at the Royal Adelaide Hospital, believes a mutation in this genetic pathway could promote the spread of ovarian cancer in patients.

"The laboratory tests have been conclusive that the intact gene prevents the spread of ovarian cancer. If we're able to better understand what's preventing these genes from functioning normally, this could be of significant interest for further research," Professor Oehler says.

"Ovarian cancer is the most lethal gynecological cancer world wide, and a better understanding of the molecular mechanisms responsible for its origin and progression are warranted to improve patient survival."

Associate Professor Grtzner says this research is an example of how basic science comparing species as different as platypus and humans can make significant contributions to the understanding of human disease.


'/>"/>

Contact: Associate Professor Frank Grützner, University of Adelaide
frank.grutzner@adelaide.edu.au
61-883-134-812
University of Adelaide
Source:Eurekalert

Related medicine news :

1. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
2. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
3. Head, Body Lice Are Genetically Very Similar
4. Certain Genetic Regions May Be Tied to Osteoporosis
5. Study of half siblings provides genetic clues to autism
6. Genetic variants, tobacco exposure and lung cancer risk
7. Research Gets Closer to Genetic Roots of Glaucoma
8. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
9. Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients
10. Some women may be genetically predisposed to smoking-related hot flashes
11. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... application containerization, today announced it will co-exhibit with technology partners LG Business Solutions ... at the Marriott Metro Center in Washington D.C., will provide education and examination ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds ... highest industry standards and specifications such as ANSI, ISO and proven test methods ...
(Date:3/27/2017)... ... 2017 , ... Osteitis pubis may be commonplace and seemingly ... occurs when the muscles around the pelvis become inflamed. Over time, untreated osteitis ... as well as accompanying tenderness and weakness. Without proper intervention, it can hinder ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a Farmingdale, ... recent RNA methylation “gold rush” with their established portfolio of optimized assay kits ... N6-methyladenosine, or m6A , RNA methylation has received a new burst in ...
(Date:3/27/2017)... San Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still ... one of the best days I’ve had in a long time,” she said. , She ... a lot of money that I never thought I would have to help my students.” ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology: